Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
暂无分享,去创建一个
R. Labianca | L. Cavanna | G. Beretta | R. Bianco | A. Morabito | R. Berardi | A. Zaniboni | C. Mosconi | S. Cascinu | S. Mosconi | C. Gallo | M. Piccirillo | F. Perrone | D. Ferrari | A. Sobrero | A. Bittoni | A. Spallanzani | F. Negri | S. Leo | D. Bilancia | M. Banzi | S. Noventa | R. Marciano | A. Casadei Gardini | D. Ferrara
[1] Edward J. Kim,et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. , 2020, The lancet. Gastroenterology & hepatology.
[2] P. Philip,et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. , 2019, Cancer treatment reviews.
[3] M. Reni,et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. , 2018, European Journal of Cancer.
[4] D. Harvey,et al. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials , 2017, Annals of Surgical Oncology.
[5] I. Ilic,et al. Epidemiology of pancreatic cancer , 2016, World journal of gastroenterology.
[6] A. Khorana,et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Ferlay,et al. More deaths from pancreatic cancer than breast cancer in the EU by 2017 , 2016, Acta oncologica.
[8] T. Conroy,et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.
[9] David Goldstein,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.
[10] T. Conroy,et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] W. Fulp,et al. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer , 2015, Journal of Gastrointestinal Cancer.
[12] H. Kennecke,et al. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer , 2015, Cancer medicine.
[13] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[14] Maximilian Reichert,et al. EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.
[15] David Cella,et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[17] J. Vauthey,et al. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: Rationale and Overview of the Conference , 2009, Annals of Surgical Oncology.
[18] B. Chauffert,et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.